Rosette Nanotubes (RNTs), a self-assembled supramolecular nanomolecule composed of fused guanine-cytosine (G^C) bases, provide a novel and innovative modality for the delivery of gene therapeutics to target cells with high efficacy. This study aims at utilizing RNTs as a nanocarrier platform for the delivery of small interfering RNA (siRNA) to knockdown oncogenic genes to facilitate the elimination of cancer from the body. By conjugating positively charged lysine functional groups to the surface of the RNTs, the nanotubes gain the ability to complex negatively charged siRNA through electrostatic interactions. Through specialized FRET-labeled siRNA and gel retardation assay, we have shown that cationic charges on the RNTs strongly affect the binding interaction and the intracellular delivery of the RNT-siRNA nancomplex. Improved gene silencing capabilities were also exhibited compared to commercially available siRNA transfection agents.

Utilizing Rosette nanotubes for the delivery of siRNA for cancer therapeutics

250th National Meeting (2015)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.